M. Templeton

Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis

D. Bajorin, A. Houghton, P. Chapman, 1993, Cancer.

Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma.

Y. Tao, H. Thaler, D. Bajorin, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase II trial of high‐dose cisplatin and dacarbazine. Lack of efficacy of high‐dose, cisplatin‐based therapy for metastatic melanoma

D. Bajorin, A. Houghton, P. Chapman, 1991, Cancer.

Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites.

C. Cordon-Cardo, A. Houghton, L. Old, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer.

J. Gabrilove, E. Casper, H. Oettgen, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.

C. Hudis, L. Norton, J. Baselga, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A 3-nitro triazole as a hypoxic cell sensitizer.

E. Hall, M. Astor, B. Hartog, 1983, British Journal of Cancer.

Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma.

C. Cordon-Cardo, D. Bajorin, D. Coit, 1990, Cancer research.

Synthesis and Properties of 10-Benzylaminopterin

F. Sirotnak, P. Chello, M. A. Templeton, 1979 .